glp 1 agonist heart disease Frontiers Breakthrough of the Year: GLP-1

The presence of structured programs ensures that individuals never feel like they are navigating alone

SC semaglutide significantly attenuates aortic plaque lesions in nondiabetic low-density-lipoprotein-receptor-deficient mice in a dose-independent manner and affects genes related to atherosclerosis [50]

Retatrutide: the triple agonist If tirzepatide was revolutionary as a dual agonist, retatrutide aims to be transformative as a triple agonist

In clinical trials with primary endpoints ranging from 26 to 52 weeks, weight change was a secondary endpoint

0.7 mL equivalent oral gavage and 20 mL gavage rinse

Dealmaking and Investment Trends Strategic dealmaking has become a defining feature of the obesity therapeutics landscape